Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 35
2017 289
2018 404
2019 464
2020 688
2021 575
2022 686
2023 832
2024 397

Text availability

Article attribute

Article type

Publication date

Search Results

4,367 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Opat S, et al. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668. Blood Adv. 2023. PMID: 37682792 Free PMC article. Clinical Trial.
Add-on erythropoietin in autoimmune hemolytic anemia.
Moser MM, Jilma B. Moser MM, et al. Blood Adv. 2024 Mar 12;8(5):1320-1321. doi: 10.1182/bloodadvances.2023012297. Blood Adv. 2024. PMID: 38470435 Free PMC article. No abstract available.
Maybe you can't drive this CAR?
Derman BA. Derman BA. Blood Adv. 2024 Feb 27;8(4):1030-1031. doi: 10.1182/bloodadvances.2023012244. Blood Adv. 2024. PMID: 38411994 Free PMC article. No abstract available.
Bridging therapy before axi-cel for lymphoma.
Belbachir S, Purtill D. Belbachir S, et al. Blood Adv. 2024 Feb 27;8(4):1051-1052. doi: 10.1182/bloodadvances.2023012128. Blood Adv. 2024. PMID: 38411993 Free PMC article. No abstract available.
Under AI's lens: spotting mutations visually.
Fein JA, Patel SS. Fein JA, et al. Blood Adv. 2024 Feb 13;8(3):827-828. doi: 10.1182/bloodadvances.2023012196. Blood Adv. 2024. PMID: 38349670 Free PMC article. No abstract available.
Celebrating a year of cancer research in Blood Advances.
Bollard CM, Weyrich A. Bollard CM, et al. Blood Adv. 2023 Dec 26;7(24):7621-7623. doi: 10.1182/bloodadvances.2023011867. Blood Adv. 2023. PMID: 38147360 Free PMC article. No abstract available.
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Nastoupil LJ, Hess G, Pavlovsky MA, Danielewicz I, Freeman J, García-Sancho AM, Glazunova V, Grigg A, Hou JZ, Janssens A, Kim SJ, Masliak Z, McKay P, Merli F, Munakata W, Nagai H, Özcan M, Preis M, Wang T, Rowe M, Tamegnon M, Qin R, Henninger T, Curtis M, Caces DB, Thieblemont C, Salles G. Nastoupil LJ, et al. Blood Adv. 2023 Nov 28;7(22):7141-7150. doi: 10.1182/bloodadvances.2023010298. Blood Adv. 2023. PMID: 37722354 Free PMC article. Clinical Trial.
Haplo ever after: haplo PTCy for children.
Talano JA, Broglie L. Talano JA, et al. Blood Adv. 2023 Sep 26;7(18):5637-5638. doi: 10.1182/bloodadvances.2023010755. Blood Adv. 2023. PMID: 37756536 Free PMC article. No abstract available.
4,367 results